Skip to main content

Hydroxychloroquine Shows No Benefit in Hospitalized COVID-19 Patients

The NEJM reports on a controlled clinical trial showing patients hospitalized with Covid-19 given hydroxychloroquine (HCQ) do not have a lower incidence of death compared to those receiving routine care.

A total of 4716 patients who were hospitalized with Covid-19 were randomly to receive HCQ (1561 patients) or usual care (3155). The primary endpoint was 28-day mortality.

Death rates at 28 days were:

  • HCQ: 421 patients (27.0%)
  • Usual care: 790 (25.0%) (rate ratio, 1.09; 95% confidence interval [CI], 0.97 to 1.23; P=0.15).

Hospital discharge within 28 days was the same between groups (59.6% vs. 62.9%).

These findings confirm earlier uncontrolled and controlled reports showing hydroxychloroquine to have no protective effects in treating Covid-19 patients. 

ADD THE FIRST COMMENT

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

Disclosures
The author has no conflicts of interest to disclose related to this subject